SG11201907315PA - Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient - Google Patents

Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient

Info

Publication number
SG11201907315PA
SG11201907315PA SG11201907315PA SG11201907315PA SG11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA
Authority
SG
Singapore
Prior art keywords
singapore
myopia
international
agent
osaka
Prior art date
Application number
SG11201907315PA
Other languages
English (en)
Inventor
Donald Tan
Roger Beuerman
Seang-Mei Saw
Aradhana Upadhyay
Masatomo Kato
Takaaki Inaba
Original Assignee
Singapore Health Serv Pte Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd, Santen Pharmaceutical Co Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11201907315PA publication Critical patent/SG11201907315PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Prostheses (AREA)
  • Undergarments, Swaddling Clothes, Handkerchiefs Or Underwear Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201907315PA 2017-03-23 2018-03-22 Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient SG11201907315PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201702378S 2017-03-23
PCT/JP2018/011361 WO2018174149A1 (en) 2017-03-23 2018-03-22 Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient

Publications (1)

Publication Number Publication Date
SG11201907315PA true SG11201907315PA (en) 2019-09-27

Family

ID=63586549

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907315PA SG11201907315PA (en) 2017-03-23 2018-03-22 Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient

Country Status (11)

Country Link
US (1) US11642350B2 (ja)
EP (1) EP3600306A4 (ja)
JP (1) JP7016880B2 (ja)
KR (1) KR102633606B1 (ja)
CN (1) CN110505876A (ja)
CA (1) CA3055891A1 (ja)
EA (1) EA201992234A1 (ja)
PH (1) PH12019502145A1 (ja)
SG (1) SG11201907315PA (ja)
TW (1) TWI816660B (ja)
WO (1) WO2018174149A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020290414A1 (en) * 2019-06-10 2021-12-02 Jenivision Inc. Methods and formulations for treating vision disorders
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200468A1 (en) 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
IL149984A0 (en) 2000-10-12 2002-12-01 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
SG151148A1 (en) * 2007-10-05 2009-04-30 Singapore Health Services Pte Method and/or kit for determining response to muscarinic receptor antagonist treatment
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
KR20180014825A (ko) * 2015-06-18 2018-02-09 프레스바이오피아 세라피스, 엘엘씨 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법
AU2017250002B2 (en) * 2016-04-11 2022-12-22 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier

Also Published As

Publication number Publication date
EP3600306A4 (en) 2020-12-02
US20200147098A1 (en) 2020-05-14
TWI816660B (zh) 2023-10-01
CN110505876A (zh) 2019-11-26
KR102633606B1 (ko) 2024-02-02
US11642350B2 (en) 2023-05-09
CA3055891A1 (en) 2018-09-27
TW201840313A (zh) 2018-11-16
JP2020514347A (ja) 2020-05-21
JP7016880B2 (ja) 2022-02-07
PH12019502145A1 (en) 2020-06-15
EP3600306A1 (en) 2020-02-05
KR20190127885A (ko) 2019-11-13
EA201992234A1 (ru) 2020-02-05
WO2018174149A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
SG11201809822SA (en) Atropine-containing aqueous composition
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907034PA (en) Methods of treating influenza
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201906222WA (en) Jak1 selective inhibitors
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201805001UA (en) Method of treating influenza a
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201804405PA (en) Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration
SG11201810801QA (en) Brain delivery protein
SG11201908052PA (en) Lipid-based nanoparticles with enhanced stability
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201907217RA (en) Pharmaceutical combinations for treating cancer
SG11201908513RA (en) Peptides for treatment of diabetes